GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pangenomic Health NARA.CN · CAD

N/A · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.30

—

Close of 4 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in CAD, from our data supplier.

FY2025

Net income

−C$3.4m

FY2019FY2025

Free cash flow

−C$1.9m

FY2019FY2025

Shareholders' equity

−C$2.2m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Research and development—C$17,722C$253,784C$534,113C$129,669——
Operating income−C$3.4m−C$1.2m−C$2.9m−C$3.6m−C$868,655−C$136,900−C$3,400
Net income−C$3.4m−C$3.8m−C$3.0m−C$12.0m−C$2.6m−C$140,000−C$3,400
Diluted earnings per share-0.13-0.59-1.42-6.35-2.84-0.03-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsC$160,910C$39,162C$71,478C$504,142C$2.6mC$147,200C$5,600
Cash and short-term investments—————C$38,200C$2,200
Total liabilitiesC$2.3mC$2.4mC$2.2mC$719,252C$334,454C$136,300C$3,200
Debt—————C$27,500—
Shareholders' equity−C$2.2m−C$2.4m−C$2.1m−C$215,110C$2.2mC$11,000C$2,400
Shares outstanding26m6m2m2m1m5m47m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−C$1.9m−C$58,253−C$1.6m−C$2.8m−C$1.1m−C$37,500−C$6,600
Capital spending——−C$3,142−C$6,005−C$6,814——
Free cash flow−C$1.9m−C$58,253−C$1.6m−C$2.8m−C$1.1m−C$37,500−C$6,600

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−C$557,240−C$899,254−C$851,244−C$1.7m−C$424,161−C$396,786−C$520,566−C$197,220
Net income−C$685,337−C$925,803−C$871,209−C$1.8m−C$396,978−C$400,628−C$845,366−C$197,681
Diluted earnings per share-0.03-0.04-0.03-0.07-0.03-0.03-0.13-0.03
Cash from operations———−C$1.0m————
Total assetsC$157,725C$169,580C$160,910C$270,903C$39,290C$35,531C$39,162C$62,752
Shareholders' equity−C$2.8m−C$2.5m−C$2.2m−C$1.8m−C$2.3m−C$1.9m−C$2.4m−C$1.6m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-2.3%90.1%—
Net income-34.1%89.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2022
Price to earnings-2.2-0.1-0.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 5-to-1 reverse split · 14 Nov 2024
  • 10-to-1 reverse split · 21 Mar 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.